Home » Stocks » ZNTL

Zentalis Pharmaceuticals, Inc. (ZNTL)

Stock Price: $50.56 USD -0.43 (-0.84%)
Updated Jul 26, 2021 9:44 AM EDT - Market open
Market Cap 2.29B
Revenue (ttm) n/a
Net Income (ttm) -151.62M
Shares Out 44.88M
EPS (ttm) -4.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $50.56
Previous Close $50.99
Change ($) -0.43
Change (%) -0.84%
Day's Open 50.96
Day's Range 50.56 - 51.77
Day's Volume 15,285
52-Week Range 25.41 - 62.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK and SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...

3 weeks ago - GlobeNewsWire

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) priced an underwritten public offering of 3.1 million shares at $48.50 per share, for gross proceeds of approximately $150.4 million. The stock's last close p...

3 weeks ago - Benzinga

NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...

3 weeks ago - GlobeNewsWire

NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...

3 weeks ago - GlobeNewsWire

SAN DIEGO--(BUSINESS WIRE)-- #LengoTx--Lengo Therapeutics, a biopharmaceutical company developing novel precision medicines targeting driver mutations in oncology, today announced the appointment of Eno...

4 weeks ago - Business Wire

NEW YORK and SAN DIEGO, May 28, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule th...

1 month ago - GlobeNewsWire

Reported robust initial results from the Phase 1 monotherapy dose escalation trial of its WEE1 inhibitor, ZN-c3, demonstrating single-agent activity and Exceptional Responses in heavily pre-treated pati...

2 months ago - GlobeNewsWire

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) has announced initial efficacy and safety data from the Phase 1 dose-escalation portion of its ongoing Phase 1/2 trial evaluating ZN-c3 in patients with advan...

3 months ago - Benzinga

ZN-c3 is currently being evaluated in patients with advanced solid tumors and ovarian cancer ZN-c3 is currently being evaluated in patients with advanced solid tumors and ovarian cancer

3 months ago - GlobeNewsWire

ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors

3 months ago - GlobeNewsWire

Initiated multiple early-stage clinical trials evaluating its oral SERD, ZN-c5, WEE1 inhibitor, ZN-c3 and BCL-2 inhibitor, ZN-d5

4 months ago - GlobeNewsWire

Additional preclinical data on ZN-c3 and the Company's EGFR inhibitor, ZN-e4, will be presented as poster presentations Additional preclinical data on ZN-c3 and the Company's EGFR inhibitor, ZN-e4, will...

4 months ago - GlobeNewsWire

NEW YORK and SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...

5 months ago - GlobeNewsWire

NEW YORK & SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule the...

5 months ago - GlobeNewsWire

NEW YORK and SAN DIEGO, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...

5 months ago - GlobeNewsWire

Zentalis (ZNTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

5 months ago - Zacks Investment Research

Andreas Halvorsen (Trades, Portfolio) has revealed a reduction in his holding of Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL), according to GuruFocus' Real-Time Picks, a Premium feature.

7 months ago - GuruFocus

NEW YORK and SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...

8 months ago - GlobeNewsWire

Live webcast to be held on September 24th at 12:00 p.m. EDT Live webcast to be held on September 24th at 12:00 p.m. EDT

10 months ago - GlobeNewsWire

NEW YORK and SAN DIEGO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecul...

10 months ago - GlobeNewsWire

Closed initial public offering (IPO) of common stock, raising gross proceeds of ~$190.0 million Raised an additional ~$144.4 million in gross proceeds from recent follow-on offering Completed a $20....

11 months ago - GlobeNewsWire

NEW YORK and SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule...

11 months ago - GlobeNewsWire

NEW YORK and SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule...

11 months ago - GlobeNewsWire

NEW YORK & SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule t...

11 months ago - GlobeNewsWire

NEW YORK and SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule...

1 year ago - GlobeNewsWire

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

Other stocks mentioned: BIO, FMTX, IMRA, KROS, PCVX, RNA, RPTX ...
1 year ago - CNN Business

NEW YORK and SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule...

1 year ago - GlobeNewsWire

The company's share price has nearly tripled since its IPO less than two months ago. Is it too late to get in on the fun?

1 year ago - The Motley Fool

NEW YORK, SAN DIEGO and DURHAM, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) and Tavros Therapeutics, Inc., today announced a strategic collaboration to apply T...

1 year ago - GlobeNewsWire

Zentera will be the sole licensee of three Zentalis discovered therapies for development and commercialization in China Zentera will be the sole licensee of three Zentalis discovered therapies for devel...

1 year ago - GlobeNewsWire

Zentera will be the sole licensee of three Zentalis discovered therapies for development and commercialization in China Zentera will be the sole licensee of three Zentalis discovered therapies for devel...

1 year ago - GlobeNewsWire

Completed initial public offering of common stock, raising approximately $190.0 million in gross proceeds

1 year ago - GlobeNewsWire

ZN-d5 is the Company’s fourth product candidate to receive IND clearance in five years ZN-d5 is the Company’s fourth product candidate to receive IND clearance in five years

1 year ago - GlobeNewsWire

These companies just raised significant cash to advance promising drug pipelines.

Other stocks mentioned: KROS
1 year ago - The Motley Fool

Biotech pharmaceutical company Zentalis Pharmaceuticals has launched a successful IPO that values the company at over $730 million.

1 year ago - Seeking Alpha

About ZNTL

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical tri... [Read more...]

Industry
Biotechnology
IPO Date
Apr 3, 2020
Stock Exchange
NASDAQ
Ticker Symbol
ZNTL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for ZNTL stock is "Strong Buy." The 12-month stock price forecast is 72.14, which is an increase of 42.68% from the latest price.

Price Target
$72.14
(42.68% upside)
Analyst Consensus: Strong Buy